For the treatment of mild to moderate cases of Covid-19, Sun Pharmaceutical Industries Limited has launched FluGuard (Favipiravir 200 mg) at a price of Rs. 35 per tablet. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease. The company will work closely with the government and medical community to ensure the availability of FluGuard to patients across the country. The stocks of FluGuard will be available in the market from this week.
CEO of India Business, Sun Pharma, Kirti Ganorkar said, with over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. Sun Pharma is launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with the company’s continuous efforts to support India’s pandemic response, he added.
